Why It Matters

Elevance Health is defending its business model against mounting congressional pressure. Lawmakers are scrutinizing Medicare Advantage costs, implementing Medicaid work requirements that will shrink enrollment, threatening the expiration of ACA premium subsidies, and launching an unprecedented bipartisan assault on pharmacy benefit manager practices. For Elevance—which operates major MA and Medicaid plans plus its own PBM—these legislative threats directly endanger core revenue streams.

By the Numbers

The company’s $2.04 million Q3 lobbying push aims to shape PBM reform legislation, preserve enhanced ACA tax credits, and influence Medicare Advantage payment policies before Congress locks in rules that could fundamentally reshape industry profitability.

Elevance Health Inc. deployed a seven-person team of registered lobbyists. The company has maintained a dominant Washington presence since 2003, accumulating 78 disclosures totaling $98.4 million over two decades.

The in-house team combines deep congressional experience with institutional knowledge. Samuel J. Marchio II and Elizabeth P. Hall anchor the effort, representing Elevance since 2011 across 55-56 disclosures each. Marchio served a decade in the House, including as Chief of Staff and on the Rules Committee. Hall worked on the Senate HELP Committee under Majority Leader Bill Frist.

Three newer additions strengthen specialized focus areas: Timothy James Drumm (October 2022, seven years House experience), Ladan Ahmadi (July 2024, Democratic House communications expertise), and Benjamin L. Steinhafel (prior Blue Cross Blue Shield Association lobbying experience).

The Agenda

Elevance Health Inc. is lobbying Congress on four core healthcare issues central to its business operations.

Medicare Advantage and Medicaid policy represents a major focus, with lobbying on supplemental benefits and ongoing eligibility re-determinations. Congress is scrutinizing Medicare Advantage costs, with recent hearings highlighting that MA plans cost taxpayers approximately 20% more than traditional Medicare—$84 billion in additional payments due to a "broken risk adjustment system."

Pharmacy Benefit Manager reform represents perhaps Elevance’s most critical priority. The company operates CarelonRx and is engaging on the Pharmacy Benefit Manager Transparency Act of 2025 (S. 526), which would ban spread pricing and require PBMs to pass 100% of rebates to health plans. Rep. Earl "Buddy" Carter and 12 bipartisan members introduced the PBM Reform Act in July 2025.

On insurance and healthcare affordability, Elevance is lobbying on ACA Exchanges and Enhanced Advanced Premium Tax Credits. The enhanced tax credits expire at year’s end absent Congressional action, creating marketplace instability affecting Elevance’s individual insurance operations.

The company is also engaging on veterans healthcare programs, aligning with efforts like the Veterans ACCESS Act.

Broader Context

Medicare Advantage faces unprecedented scrutiny, with lawmakers concerned that the program costs taxpayers approximately 20 percent more than traditional Medicare. President Trump’s budget reconciliation package implemented nationwide Medicaid work requirements effective January 2027, expected to result in 5.2 million adults losing coverage by 2034.

PBM reform has emerged as one of the most active bipartisan healthcare efforts in Congress. The Federal Trade Commission released a report finding that PBMs steer patients to affiliated pharmacies for profitable drugs, threatening Elevance’s CarelonRx subsidiary. Enhanced Advanced Premium Tax Credits supporting ACA Marketplace enrollees are set to expire at year-end 2025, creating marketplace instability.

Between The Lines

Prior authorization denials remain a flashpoint, with bipartisan bills like the Improving Seniors’ Timely Access to Care Act pushing for reform. The momentum on PBM reform is particularly concerning for Elevance, as Carter’s bipartisan coalition targets spread pricing and demands greater transparency—directly challenging CarelonRx’s business model.

Healthcare price transparency regulations continue taking effect for 2025, with Congress pushing for even stricter disclosure requirements through multiple bills.

Competitive Landscape

Elevance operates in a crowded lobbying environment where other major health insurers pursue nearly identical policy agendas. UnitedHealth Group Inc. and Kaiser Foundation Health Plan Inc. both lobby extensively on overlapping issues including Medicare Advantage, Medicaid coverage, and PBM reforms.

The significant overlap underscores how critical current congressional debates are to the entire sector. This creates an intensely competitive advocacy environment where messaging, access, and strategic positioning matter enormously to influence policy outcomes.

The Bottom Line

Elevance Health Inc. spent $2.04 million on lobbying in Q3 2025 amid significant healthcare policy upheaval. The company faces four interconnected challenges: Medicare Advantage cost scrutiny, bipartisan PBM reform efforts, Medicaid work requirements reducing enrollment, and potential expiration of ACA premium tax credits. While Elevance’s seven-person team brings strong Hill experience, competitors like UnitedHealth and Kaiser are lobbying on virtually identical issues. The legislative momentum suggests substantial headwinds ahead.

Spot something wrong? Report an issue with this article